Evidence map›Paper›PMID 41726319›Full record

ArticleTherapeutic advances in neurological disorders2026

Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.

Qian Zhou, Yuzhen Ouyang, Fei Jiang, Qiuming Zeng, Ting He, Zeyi Wen, Guanzhong Shi, Xiaohua Dong, Haobing Cai, Wei Xiang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in neurological disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qian ZhouDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.ORCID https://orcid.org/0000-0002-2890-1076
Yuzhen OuyangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Fei JiangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Qiuming ZengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Ting HeDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Zeyi WenDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Guanzhong ShiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Xiaohua DongDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Haobing CaiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Wei XiangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Miao SuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Kailin LiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Huan YangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha 410000, Hunan, P.R. China.ORCID https://orcid.org/0000-0002-8690-2544

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ofatumumab (OFA), a humanized anti-CD20 monoclonal antibody, shows potential in myasthenia gravis (MG) with antibody against acetylcholine receptor (AChR-Ab), but comparative efficacy across AChR and muscle-specific kinase (MuSK) subtypes remains uncharacterized. Objectives: To evaluate OFA's clinical and immunological effects in AChR-MG versus MuSK-MG, identify predictors of minimal symptom expression (MSE), and explore the dynamics of B-cell repopulation. Design: A retrospective study in a single center. Methods: Twenty-one refractory MG patients (13 MuSK+, 8 AChR+) received individualized OFA induction (Regimen 1: two 20 mg doses ⩾2 weeks apart; Regimen 2: single 20 mg dose) and maintenance (20 mg upon CD19 + B counts ⩾5 cells/μL repopulation or clinical exacerbation). Outcomes included time-to-MSE, Quantitative Myasthenia Gravis Score (QMGS) dynamics, prednisone reduction, and serial immunophenotyping (B-cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), soluble CD40L (sCD40L), microphage migration inhibitory factor (MIF), and immunoglobulin). Results: MuSK-MG achieved faster MSE (median time: 6 vs 15 months, log-rank Conclusion: OFA demonstrates superior efficacy in MuSK-MG with distinct immunological modulation. AChR-MG requires combinatorial strategies targeting compensatory pathways.

Indexed as

acetylcholine receptorAPRILBAFFimmunoglobulinMIFmuscle-specific kinasemyasthenia gravisofatumumabsCD40L

Identifiers

PMID41726319
PMCPMC12921211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.